applicable across many diseases – including autoimmune, immunoinflammatory, metabolic, neurological, neuroinflammatory diseases, and cancer. Monoclonal microbials have the potential to fundamentally change traditional models of drug discovery and development. By finding and selecting naturally occurring monoclonal microbial with defined therapeutic effects, Evelo can improve the speed, cost, and success of drug discovery and development. Evelo’s platform enables pharmacological intervention at all stages of the disease with naturally occurring, safe, and effective monoclonal microbials. Evelo Biosciences was conceived and created within VentureLabs®, Flagship Pioneering’s institutional innovation foundry, and launched by Flagship in 2015.